Liseth de Wolff

Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure

Suzanne Arends, Liseth de Wolff, Jolien F. van Nimwegen et al. · The Lancet Rheumatology · 2021 · 65 citations · Full text

Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle‐controlled trial

Korting Hc, Claudia Schöllmann, W Cholcha et al. · Journal of the European Academy of Dermatology and Venereology · 2010 · 55 citations

Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial

Liseth de Wolff, Jolien F. van Nimwegen, Esther Mossel et al. · Seminars in Arthritis and Rheumatism · 2022 · 36 citations · Full text

Ten years of the ESSDAI: is it fit for purpose?

Liseth de Wolff, Suzanne Arends, Jolien F. van Nimwegen et al. · PubMed · 2020 · 26 citations

Composite Endpoint, Education, Psoriatic Arthritis +18

Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell–Targeted Therapy in the Trial of Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS)

Elena Pontarini, Elisabetta Sciacca, Farzana Chowdhury et al. · Arthritis & Rheumatology · 2023 · 19 citations · Full text